|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Outsourcing Outlook: Contract Services' Crystal Ball
Author(s)Jim Miller
by Jim Miller, Bio/Pharmaceutical Outsourcing Report Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.
Advertisement
Articles in this issue
over 22 years ago
Becoming a Partner of Choice and Evaluating Prospective Alliancesover 22 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 22 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 22 years ago
Survival Strategies: Keeping Tabs on TrainingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
